Literature DB >> 26959614

NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics.

Deepak Kumar1, Ashish Gupta1, Kavindra Nath2.   

Abstract

Advances in the application of NMR spectroscopy-based metabolomic profiling of prostate cancer comprises a potential tactic for understanding the impaired biochemical pathways arising due to a disease evolvement and progression. This technique involves qualitative and quantitative estimation of plethora of small molecular weight metabolites of body fluids or tissues using state-of-the-art chemometric methods delivering an important platform for translational research from basic to clinical, to reveal the pathophysiological snapshot in a single step. This review summarizes the present arrays and recent advancements in NMR-based metabolomics and a glimpse of currently used medical imaging tactics, with their role in clinical diagnosis of prostate cancer.

Entities:  

Keywords:  MRSI; Metabolomics; NMR spectroscopy; PET; clinical intervention; prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 26959614     DOI: 10.1586/14737159.2016.1164037

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  9 in total

Review 1.  NMR-based metabolomics studies of human prostate cancer tissue.

Authors:  Ana Rita Lima; Joana Pinto; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho
Journal:  Metabolomics       Date:  2018-06-18       Impact factor: 4.290

Review 2.  Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.

Authors:  Bo Yang; Guo-Qiang Liao; Xiao-Fei Wen; Wei-Hua Chen; Sheng Cheng; Jens-Uwe Stolzenburg; Roman Ganzer; Jochen Neuhaus
Journal:  J Zhejiang Univ Sci B       Date:  2017 Nov.       Impact factor: 3.066

3.  Amino Acid Profiles of Serum and Urine in Search for Prostate Cancer Biomarkers: a Pilot Study.

Authors:  Paweł Dereziński; Agnieszka Klupczynska; Wojciech Sawicki; Jerzy A Pałka; Zenon J Kokot
Journal:  Int J Med Sci       Date:  2017-01-01       Impact factor: 3.738

4.  Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance.

Authors:  Hyun-Hwi Kim; In Hye Jeong; Ja-Shil Hyun; Byung Soo Kong; Ho Jin Kim; Sung Jean Park
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

Review 5.  Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers.

Authors:  Nuria Gómez-Cebrián; Ayelén Rojas-Benedicto; Arturo Albors-Vaquer; José Antonio López-Guerrero; Antonio Pineda-Lucena; Leonor Puchades-Carrasco
Journal:  Metabolites       Date:  2019-03-08

Review 6.  Potential of nuclear magnetic resonance metabolomics in the study of prostate cancer.

Authors:  R Ravikanth Reddy; Naranamangalam R Jagannathan
Journal:  Indian J Urol       Date:  2022-04-01

7.  Comprehensive biomarker profiles and chemometric filtering of urinary metabolomics for effective discrimination of prostate carcinoma from benign hyperplasia.

Authors:  Eleonora Amante; Andrea Cerrato; Eugenio Alladio; Anna Laura Capriotti; Chiara Cavaliere; Federico Marini; Carmela Maria Montone; Susy Piovesana; Aldo Laganà; Marco Vincenti
Journal:  Sci Rep       Date:  2022-03-14       Impact factor: 4.379

8.  Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.

Authors:  Peder R Braadland; Guro Giskeødegård; Elise Sandsmark; Helena Bertilsson; Leslie R Euceda; Ailin F Hansen; Ingrid J Guldvik; Kirsten M Selnæs; Helene H Grytli; Betina Katz; Aud Svindland; Tone F Bathen; Lars M Eri; Ståle Nygård; Viktor Berge; Kristin A Taskén; May-Britt Tessem
Journal:  Br J Cancer       Date:  2017-10-03       Impact factor: 7.640

Review 9.  The Metabolic Phenotype of Prostate Cancer.

Authors:  Eric Eidelman; Jeffrey Twum-Ampofo; Jamal Ansari; Mohummad Minhaj Siddiqui
Journal:  Front Oncol       Date:  2017-06-19       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.